Claims
- 1. The compound which is 7-chloro-5-iodo-4-oxo-1,4-dihydroquinoline-2-carboxylic acid.
- 2. A compound of formula II: ##STR12## wherein R.sup.2 is a group of formula (iii): ##STR13## in which Z is O or NH; R.sup.c represents C.sub.1-6 alkylene optionally substituted with a C.sub.1-6 alkyl group; R.sup.d and R.sup.e independently represent C.sub.1-6 alkyl, aryl or aryl (C.sub.1-6)alkyl, or R.sup.d and R.sup.e together with the intervening nitrogen atom represent a pyrrolidino, piperidino or morpholino group; R.sup.6 is hydrogen; and R.sup.5 and R.sup.7 are selected from the group consisting of C.sub.1-6 alkyl and halogen.
- 3. A compound according to claim 2 selected from the group consisting of:
- 2-(diethylamino)ethyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- 5. 7-dichloro-2-(2-dimethylaminoethyl)carbamoyl-4-oxo-1,4-dihydroquinoline;
- 2-(1-pyrrolidinyl)ethyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- 2-(4-morpholinyl)ethyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- 5,7-dichloro-2-[2-(4-morpholinyl)ethyl]carbamoyl-4-oxo-1,4-dihydroquinoline
- 5,7-dichloro-2-[2-(1-pyrrolidinyl)ethyl]carbamoyl-4-oxo-1,4-dihydroquinoline;
- 2-(diisopropylamino)ethyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- 3-(dimethylamino)propyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- (2-dimethylamino-1-methyl)ethyl 5,7-dichloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;
- 2-(diethylamino)ethyl 7-chloro-5-iodo-4-1,4-dihydroquinoline-2-carboxylate; and
- 2-(diethylamino)ethyl 7-bromo-5-ethyl-4-oxo-1,4-dihydroquinoline-2-carboxylate.
- 4. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.
- 5. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 and a pharmaceutically acceptable carrier or excipient.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8719102 |
Aug 1987 |
GBX |
|
BRIEF DESCRIPTION OF RELATED APPLICATIONS
The present invention is a continuation of U.S. Ser. No. 07/716,435, filed Jun. 17, 1991, now abandoned, being a continuation of U.S. Ser. No. 07/533,255, file on Jun. 4, 1990, now abandoned, being a continuation of U.S. Ser. No. 07/228,191, filed Aug. 4, 1988, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4328230 |
Brown et al. |
May 1982 |
|
5026700 |
Harrison et al. |
Jun 1991 |
|
5028707 |
Nichols et al. |
Jul 1991 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
2554772 |
May 1975 |
DEX |
1207771 |
Mar 1969 |
GBX |
1334705 |
Jun 1970 |
GBX |
Non-Patent Literature Citations (6)
Entry |
Evans, et al., Br. J. Pharmac., vol. 91 (1987) pp. 531-537. |
Mutschler Arzneimittelwirkungen 5th Edition (1986), pp. 555-566. |
Perkins, et al., Chem. Abs. 99, No. 25 (Dec. 19, 1983) p. 139, 206826b. |
Neumuller Rompps Chemie-Lexikon (8th Ed.) 3 p. 2296 (1983). |
Daeniker, et al., Chem. Abs. 54, No. 538 (1960). |
Heindel, et al., J. Med. Chem. II, pp. 1218-1221 (1968). |
Continuations (3)
|
Number |
Date |
Country |
Parent |
716435 |
Jun 1991 |
|
Parent |
533255 |
Jun 1990 |
|
Parent |
228191 |
Aug 1988 |
|